WO2005079390A3 - Inhibition de la signalisation du fgf - Google Patents

Inhibition de la signalisation du fgf Download PDF

Info

Publication number
WO2005079390A3
WO2005079390A3 PCT/US2005/004682 US2005004682W WO2005079390A3 WO 2005079390 A3 WO2005079390 A3 WO 2005079390A3 US 2005004682 W US2005004682 W US 2005004682W WO 2005079390 A3 WO2005079390 A3 WO 2005079390A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulf1
exogenous
methods
fgf
fgf signaling
Prior art date
Application number
PCT/US2005/004682
Other languages
English (en)
Other versions
WO2005079390A2 (fr
Inventor
Charles P Emerson Jr
Xingbin Ai
Original Assignee
Boston Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Res Inst filed Critical Boston Biomedical Res Inst
Priority to CA002555417A priority Critical patent/CA2555417A1/fr
Priority to EP05713533A priority patent/EP1742961A4/fr
Priority to JP2006553327A priority patent/JP2007522243A/ja
Publication of WO2005079390A2 publication Critical patent/WO2005079390A2/fr
Publication of WO2005079390A3 publication Critical patent/WO2005079390A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes et des compositions qui permettent d'inhiber la signalisation du FGF (facteur de croissance des fibroblastes). Ces méthodes consistent à mettre une cellule réagissant au FGF en contact avec une endosulfatase de héparane sulfate 6-O (Sulf1) exogène à un taux efficace pour modifier le héparane sulfate endogène, inhibant ainsi la signalisation du FGF. Ces méthodes consistent également à mettre une cellule réagissant au FGF en contact avec un composé exogène modifié par Sulf1, ce dernier étant caractérisé par sa capacité à réduire la liaison de FGF2 ou de FGF4 à FGFR1. L'invention concerne également des compositions qui comprennent les composés exogènes modifiés par Sulf1, lesquelles sont destinées à être utilisées conjointement avec les méthodes selon l'invention.
PCT/US2005/004682 2004-02-13 2005-02-11 Inhibition de la signalisation du fgf WO2005079390A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002555417A CA2555417A1 (fr) 2004-02-13 2005-02-11 Inhibition de la signalisation du fgf
EP05713533A EP1742961A4 (fr) 2004-02-13 2005-02-11 Inhibition de la signalisation du fgf
JP2006553327A JP2007522243A (ja) 2004-02-13 2005-02-11 Ｆｇｆシグナリングの阻害

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54444904P 2004-02-13 2004-02-13
US60/544,449 2004-02-13

Publications (2)

Publication Number Publication Date
WO2005079390A2 WO2005079390A2 (fr) 2005-09-01
WO2005079390A3 true WO2005079390A3 (fr) 2006-12-14

Family

ID=34886037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004682 WO2005079390A2 (fr) 2004-02-13 2005-02-11 Inhibition de la signalisation du fgf

Country Status (5)

Country Link
US (1) US7968527B2 (fr)
EP (1) EP1742961A4 (fr)
JP (1) JP2007522243A (fr)
CA (1) CA2555417A1 (fr)
WO (1) WO2005079390A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200914044A (en) * 2007-07-12 2009-04-01 Daiichi Sankyo Co Ltd Anti human Sulf1 antibody
WO2009011892A2 (fr) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Utilisation de protéines sulf et sulfate d'héparan pour l'innervation et la protection neurale dépendant de gdnf
JP2011526925A (ja) * 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ，インク． ヘパラン硫酸阻害剤
CA2774999A1 (fr) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Procedes de modulation de l'autophagie par la modulation de produits geniques renforcant l'autophagie
JP5784296B2 (ja) * 2010-10-01 2015-09-24 学校法人 創価大学 神経細胞の製造方法及び神経細胞分化促進剤
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
WO2015191986A1 (fr) 2014-06-13 2015-12-17 Genentech, Inc. Méthodes de traitement et de prévention de la résistance du cancer aux médicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377385A1 (fr) * 1999-06-03 2000-12-14 Jessie L.S. Au Methodes et compositions permettant de moduler la proliferation et la mort cellulaire
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US20030147875A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002355844A1 (en) * 2001-08-01 2003-02-17 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AI X. ET AL.: "Substrate Specificity and Domain Functions of Extracellular Heparan Sulfate 6-O-Endosulfatases, QSulf1 and QSulf2", J. BIOL. CHEM., vol. 281, no. 8, 24 February 2006 (2006-02-24), pages 4969 - 4976, XP003005421 *
LAI J. ET AL.: "Loss of Hsulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer", J. BIOL. CHEM., vol. 278, no. 25, 20 June 2003 (2003-06-20), pages 23107 - 23117, XP003005420 *
LAI J.P. ET AL.: "hSulf1 Sulfatase Promotes Apoptosis of Hepatocellular Cancer Cells by Decreasing Heparin-binding Growth Factor Signaling", GASTROENTEROLOGY, vol. 126, no. 1, January 2004 (2004-01-01), pages 231 - 248, XP005313323 *
MORIMOTO-TOMITA M. ET AL.: "Cloning and Characterization of Two Extracellular Heparin-degrading Endosulfatases in Mice and Humans", J. BIOL. CHEM., vol. 277, no. 51, 20 December 2002 (2002-12-20), pages 49175 - 49185, XP002989135 *
NARITA K. ET AL.: "HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo", CANCER RES., vol. 66, no. 12, 15 June 2006 (2006-06-15), pages 6025 - 6032, XP003005422 *
See also references of EP1742961A4 *

Also Published As

Publication number Publication date
EP1742961A4 (fr) 2009-07-15
JP2007522243A (ja) 2007-08-09
WO2005079390A2 (fr) 2005-09-01
US20050227921A1 (en) 2005-10-13
US7968527B2 (en) 2011-06-28
EP1742961A2 (fr) 2007-01-17
CA2555417A1 (fr) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2005079390A3 (fr) Inhibition de la signalisation du fgf
TWI317619B (en) Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement
WO2005117557A3 (fr) Systeme d'expression
WO2007090068A3 (fr) Composes de cyanoisoquinoleine et procedes d'utilisation de ceux-ci
WO2007054623A3 (fr) Inhibiteurs de signalisation du herisson des mammiferes
PL2091988T3 (pl) Środek po włokowy o wysokiej odporności na zadrapania i odporności na działanie czynników atmosferycznych
WO2006076627A3 (fr) Methodes et compositions servant a moduler l'environnement extracellulaire de cellules souches
TW200833608A (en) Indium compositions
WO2006072615A3 (fr) Triazolophtalazines
HK1103440A1 (en) Dynamic line rating system with real-time tracking of conductor creep to establish the maximum allowable conductor loading as limited by clearance
EP2727998A3 (fr) Procédés pour la purification de cellules endodermiques pancréatiques issues de cellules souches embryonnaires humaines
WO2007075439A3 (fr) Compositions et methodes pour traiter l'obesite et des troubles metaboliques associes
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2006024640A3 (fr) Triazolophtalazines
WO2010056378A3 (fr) Compositions de matrice extracellulaire pour le traitement du cancer
WO2009070244A3 (fr) Procédés d'inhibition de la fascine
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
WO2007007207A8 (fr) Composes de modulation de la profileration cellulaire
TW200640496A (en) Visco-supplement composition and methods
IL189883A0 (en) Isoquinolines as igf-1r inhibitors
WO2006124375A3 (fr) Matieres, compositions et procedes pour prevenir et traiter des troubles inflammatoires a mediation immune
WO2012006068A3 (fr) Composés pour inhiber la prolifération cellulaire
WO2007092628A3 (fr) Procedes et compositions destinees a moduler des cellules conjonctivales caliciformes
WO2006017318A3 (fr) Methodes destinees a traiter le cancer au moyen d'agents inhibant la signalisation de wnt16

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2555417

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006553327

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005713533

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005713533

Country of ref document: EP